Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Date:8/6/2013

or the same period in fiscal 2012.

Fiscal 2013 Nine-Month Results

  • Total net revenues for the first nine-months of fiscal 2013 totaled $53.7 million, compared with $27.7 million for the first nine-months of fiscal 2012.
  • Total operating expenses were $90.6 million in the first nine-months of fiscal 2013, compared to $75.5 million in the comparable period for fiscal 2012.
  • Cash used in operations was $35.3 million in the first nine-months of fiscal 2013.
  • Net loss for the first nine-months of fiscal 2013 was $40.0 million, or $0.29 per share, compared with a net loss of $48.0 million, or $0.36 per share for the comparable period in fiscal 2012.
  • NUEDEXTA RevenueFor the quarter ended June 30, 2013, the company reported NUEDEXTA gross and net revenue of $24.3 million and $19.0 million respectively. Third quarter fiscal 2013 NUEDEXTA net revenue increased 89% versus the previous year and 15% over the previous quarter.

    Cash, Cash Equivalents & Marketable SecuritiesAs of June 30, 2013 Avanir had cash, cash equivalents and restricted investments totaling $57.5 million, including cash and cash equivalents of $55.0 million.

    Business Highlights

  • The company reported 27% unit growth of NUEDEXTA representing the ninth consecutive quarter of double-digit growth.
  • The U.S. Food and Drug Administration (FDA) agreed to an expedited development pathway for the company's next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application. Upon completion of these pre-clinical studies the company intends to proceed directly into human clinical trials.
  • The European Commission approved NUEDEXTA in the European Union for the treatment of pseudobulbar affect (PBA), irrespective of underlying neurologic disease or injury.
  • The company completed patient enrollment of PRIME, its phase II, placebo controlled study testi
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Avanir Pharmaceuticals to Participate in Two Conferences in August
    2. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
    4. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
    5. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
    6. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    7. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    8. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    9. AVANIR Pharmaceuticals To paticipate in two conferences in March
    10. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    11. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael ... clinic, GPM Pediatrics, reacts to a recent study, which shows ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 According ... to severe stress are more likely than others to grow ... before pregnancy." There were two specific types of ...
    (Date:7/24/2014)... Deutschland, und MARSEILLE , ... , Weltweite Exklusivlizenz der ... QIAGEN die Entwicklung von Tests auf SF3B1-Mutationen, ... Neuer Test weist Mutationen des ... (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
    (Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
    Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
    ... Neurosciences Inc. ("Knopp"),announced that the U.S. Food ... has granted orphan drug designation to KNS-760704 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... to evaluate the safety,tolerability and pharmacokinetics of ...
    ... to be Treated for This ... Aggressive Cancer at Home, PHILADELPHIA, ... Food and Drug Administration,(FDA) for oral HYCAMTIN(R) (topotecan) capsules for the ... are indicated for patients who had a,complete or partial response to ...
    Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 2GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 3GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 4
    (Date:7/27/2014)... July 27, 2014 The inaugural ... demonstrate their passion for protecting our environment and getting ... the Southwest, will go on hiking or camping outings, ... show their support for permanently protecting our land, water ... the Latino community’s perspective on the environment like the ...
    (Date:7/27/2014)... Vancouver, BC (PRWEB) July 27, 2014 ... have recently announced their demonstration depicting the hamstring release ... Backs in Action Wellness Center in Vancouver and have ... The hamstring release procedure was carried out by the ... The purpose of the exercise is to release tight ...
    (Date:7/27/2014)... (PRWEB) July 27, 2014 This ... Global and Chinese Dutasteride (CAS 164656-23-9) industry. The ... (CAS 164656-23-9) including its classification, application and manufacturing ... top manufacturers of Dutasteride (CAS 164656-23-9) listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
    (Date:7/27/2014)... The European Agricultural Adjuvants Market report ... analysis and forecast of revenue. The agricultural adjuvants market ... million in 2013 to $657.1 million by 2018, at ... Browse through the TOC of the European Agricultural Adjuvants ... analysis provided. It also provides a glimpse of the ...
    (Date:7/27/2014)... Bromine market report defines and segments the Bromine market in ... in European region comprises of four major countries. They are ... a dominant share of Bromine market influences the demand for ... the TOC of the Europe Bromine Market report, to get ... TOC of the Europe Bromine Market report. The report provides ...
    Breaking Medicine News(10 mins):Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
    ... Executive Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. ... the Philip Morris and R.J. Reynolds tobacco companies ... children by defeating a,ballot initiative to increase Oregon,s ... tobacco companies will profit by selling more cigarettes,while ...
    ... Solutions Announces Opportunity for Patients to Participate in ... Toward Improved Future Dialysis Options -, WARRENDALE, ... provider of advanced sorbent hemodialysis products and services,today ... has begun using,sorbent technology. The study presents the ...
    ... ALUS ), a worldwide leader in advanced patient ... financial,results on Tuesday, November 13, 2007, following the market ... the results will follow the,same day at 1:30 p.m. ... open to all interested parties live via the conference ...
    ... Revenue Impact Projected at $7.5 Million in 2008, ... product,manufacturer, Natural Nutrition Inc., (OTC Bulletin Board: NNTN), ... bar manufacturing capabilities by adding state-of-the-art,equipment to produce ... high,demand today. InterACTIVE Nutrition has been manufacturing ...
    ... Toronto Stock Exchange Symbol: DND, MISSISSAUGA, ON, Nov. 7 ... and operational results for,the three and nine months ended September ... Entered into a licensing and distribution agreement with ... was granted the exclusive right ...
    ... Laws Expected to Spread Around the Globe, ATLANTA, ... Society,s ambitious goal to cut cancer incidence by,one-fourth by ... in 2004 than they were in 1992. Despite those ... reduction over the first half of the challenge,period was ...
    Cached Medicine News:Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment 2Health News:Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment 3Health News:Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007 2Health News:Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2Health News:Cipher reports third quarter fiscal 2007 results 2Health News:Cipher reports third quarter fiscal 2007 results 3Health News:Cipher reports third quarter fiscal 2007 results 4Health News:Cipher reports third quarter fiscal 2007 results 5Health News:Cipher reports third quarter fiscal 2007 results 6Health News:Cipher reports third quarter fiscal 2007 results 7Health News:Cipher reports third quarter fiscal 2007 results 8Health News:Cipher reports third quarter fiscal 2007 results 9Health News:Cipher reports third quarter fiscal 2007 results 10Health News:Cipher reports third quarter fiscal 2007 results 11Health News:Cipher reports third quarter fiscal 2007 results 12Health News:Cipher reports third quarter fiscal 2007 results 13Health News:Cipher reports third quarter fiscal 2007 results 14Health News:Cipher reports third quarter fiscal 2007 results 15Health News:Cipher reports third quarter fiscal 2007 results 16Health News:Cipher reports third quarter fiscal 2007 results 17Health News:Cipher reports third quarter fiscal 2007 results 18Health News:Cipher reports third quarter fiscal 2007 results 19Health News:Cipher reports third quarter fiscal 2007 results 20Health News:Cancer Incidence in the United States: A Progress Report 2Health News:Cancer Incidence in the United States: A Progress Report 3
    ... a combination Spectral Optical Coherence Tomography (OCT) ... provides suberb, high-quality images of the vitreo-retina, ... of spectral technology, OTI's sytem can reach ... per second and provide images with a ...
    ... The Pulse CDC Compact Cardiac Digital Camera is ... an open, patient-friendly gantry, and provides full sized ... camera into your clinic you need a flexible ... layout. Find out how the Pulse reduces ...
    ... an ideal gamma camera for ... ability to perform bone and ... perfusion diagnosis and SPECT studies. ... and space efficient solution for ...
    ... analyzer to perform a Chem 7 panel ... Its test panel -- including sodium, potassium, ... creatinine -- represents the most commonly ordered ... hospital. The addition of hematocrit provides valuable ...
    Medicine Products: